Entropy Technologies LP Invests $239,000 in Arvinas, Inc. $ARVN

Entropy Technologies LP bought a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 32,491 shares of the company’s stock, valued at approximately $239,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its stake in Arvinas by 965.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock valued at $33,000 after purchasing an additional 4,219 shares in the last quarter. CWM LLC increased its holdings in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock worth $53,000 after buying an additional 7,300 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Arvinas in the 2nd quarter worth about $74,000. Aigen Investment Management LP purchased a new stake in shares of Arvinas during the 1st quarter valued at about $77,000. Finally, 111 Capital bought a new position in shares of Arvinas in the 2nd quarter valued at about $95,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Stock Up 2.5%

Shares of Arvinas stock opened at $12.42 on Thursday. The stock’s fifty day moving average is $9.76 and its two-hundred day moving average is $8.21. The company has a market capitalization of $797.61 million, a PE ratio of -15.33 and a beta of 2.38. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $27.00.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.27. The business had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The business’s revenue for the quarter was down 59.1% compared to the same quarter last year. During the same period last year, the company earned ($0.68) earnings per share. As a group, research analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Arvinas announced that its board has authorized a stock buyback plan on Wednesday, September 17th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the company to buy up to 17.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Briggs Morrison acquired 30,000 shares of the stock in a transaction on Monday, September 22nd. The stock was bought at an average cost of $7.57 per share, with a total value of $227,100.00. Following the transaction, the director directly owned 76,021 shares in the company, valued at approximately $575,478.97. This represents a 65.19% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.73% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ARVN has been the topic of several analyst reports. Stephens boosted their price objective on Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Arvinas in a research report on Wednesday, October 8th. Barclays increased their price target on Arvinas from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Arvinas in a research note on Tuesday, October 7th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $6.00 price objective (down previously from $8.00) on shares of Arvinas in a research report on Wednesday, October 15th. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Arvinas presently has a consensus rating of “Hold” and a consensus price target of $16.39.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.